Forty-five percent of providers interviewed by KLAS are planning to consolidate their CVIS products, but less than half plan to stick with their current vendor/solution.

In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).

CardioKinetix Inc. announced it has completed a $50 million financing led by Edwards Lifesciences Corp. with participation from other existing investors. This financing provides CardioKinetix with the capital necessary to complete the PARACHUTE IV randomized pivotal clinical trial of the Parachute ventricular partitioning device for the treatment of heart failure.

CardioCell LLC announced the treatment of its first patient in the University of Pennsylvania’s Phase IIa clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy.

Researchers at the Minneapolis Heart Institute Foundation have found that when care teams started following a new set of guidelines for certain patients recovering from cardiovascular surgery, hospital stays (and the associated costs) were reduced.

BioCardia Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s application to begin a Phase III clinical trial of its bone marrow-derived CardiAMP Therapy for heart failure. The clinical trial is a randomized, controlled, multi-center study of 250 patients evaluating CardiAMP Therapy at up to 40 clinical sites.